
Roche's vamikibart shows sustained vision improvement in uveitic macular edema, FDA decision expected by July 2027
Roche announced positive one-year Phase III trial results for vamikibart, an investigational non-steroid treatment for uveitic macular edema (UME), showing sustained vision improvement and reduced macular swelling. The FDA has accepted Roche's Biolog...





